MSH6 and Lynch syndrome: MSH2, PMS2, and MSH6 variants were identified in 0.3% (n = 3), 0.5% (n = 5), and 0.09% (n = 1), with a total of 0.9% of ovarian cancer patients having Lynch syndrome-associated variants, and 78% (7/9) of them had endometrioid, clear cell, or mixed ovarian carcinoma/carcinosarcoma, whereas two had high-grade serous ovarian carcinoma [61, 62].